NVS
Novartis AG$147.08
-1.88%LiveJun 18, 2026
Market cap
$280.64B
52w range
112.34 – 170.46
P / E
—
EPS
—
Volume
1.67M
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on Novartis AG’s valuation06-08today
- Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study6d
- Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)9d
- Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)9d
- Novartis says rare muscle disease drug shows promise in early trial10d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $141.00 (-4.13%)
Candlestick · 1Y
Open in chart workstation →NVS
147.08+25.15%H 170.46L 112.34MA50 148.93MA200 142.24Avg vol 1.8M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.52% | -3.91% | -3.08% | +0.72% | +8.10% | +6.68% | +25.15% | +54.03% | +65.52% | +121.24% | +835.03% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$147.13
259 sh
Bid
$112.77
100 sh
Ask
$184.97
100 sh
Spread
$72.200
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
DB · price_targets + analyst_gradesConsensus target
$141.00
-4.13% upside
Low
$112.00
Median
$141.00
High
$170.00
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Studyzacks.com·Jun 15, 2026
- Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)globenewswire.com·Jun 12, 2026
- Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)globenewswire.com·Jun 12, 2026
- Novartis says rare muscle disease drug shows promise in early trialreuters.com·Jun 11, 2026
- Novartis Reports Positive Data for Neuromuscular Disorder Drugzacks.com·Jun 11, 2026
- Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Studybenzinga.com·Jun 11, 2026
- Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpointglobenewswire.com·Jun 11, 2026
- Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpointglobenewswire.com·Jun 11, 2026
Financial scores
DBJun 19, 2026Altman Z
3.51
Safe
≥ 3.0 safe · 1.81–3.0 grey · < 1.81 distress
Piotroski F
6/9
Average
≥ 7 strong · 4–6 average · < 4 weak
Peers
No peer list available for NVS.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|